Higher expressional levels of OX40 and OX40L in the blood can represent the whole-body milieu and can be utilized as an alternative to repetitive tumor biopsies to evaluate the efficacy of OX40-based trials. The gene discussed is TNFRSF4; the disease is neoplasm.